Comparing Weight Loss Drugs in Psychiatric Patients: Liraglutide vs Metformin vs Others
Real-world comparison shows liraglutide, metformin, naltrexone/bupropion, and phentermine-topiramate have different weight loss efficacy, side effects, and discontinuation rates in psychiatric patients.
Quick Facts
What This Study Found
Comparative effectiveness analysis of four anti-obesity medications in psychiatric patients revealed differences in weight loss, adverse events, and early discontinuation rates in this understudied population.
Key Numbers
How They Did This
Retrospective observational cohort study comparing liraglutide, metformin, naltrexone/bupropion, and phentermine-topiramate in psychiatric outpatients.
Why This Research Matters
Psychiatric patients face unique challenges with weight management — their medications cause weight gain, some drugs interact with psychiatric medications, and mental health conditions affect adherence. Evidence specific to this population is critical.
The Bigger Picture
As obesity treatment becomes more personalized, understanding how weight loss drugs perform in specific populations like psychiatric patients is essential for equitable, effective care.
What This Study Doesn't Tell Us
Retrospective observational design; selection bias likely; short-term outcomes only; psychiatric diagnoses and medications not standardized across groups.
Questions This Raises
- ?How do newer GLP-1 drugs (semaglutide, tirzepatide) perform in psychiatric populations compared to liraglutide?
- ?Do specific psychiatric medications predict better response to certain weight loss drugs?
Trust & Context
- Key Stat:
- 4 AOMs compared in psychiatric patients Real-world comparison of weight loss drugs in a population with unique treatment challenges
- Evidence Grade:
- Retrospective observational study — provides needed real-world data but cannot prove comparative superiority.
- Study Age:
- Published in 2026, addressing a critical evidence gap in psychiatric obesity management.
- Original Title:
- Comparative efficacy and safety of liraglutide versus metformin, naltrexone/bupropion, and phentermine-topiramate in psychiatric patients.
- Published In:
- Therapeutic advances in psychopharmacology, 16, 20451253261419609 (2026)
- Authors:
- Choi, Won-Seok, Song, Min-Kyu, Seo, Mansuk, Woo, Young Sup, Bahk, Won-Myong
- Database ID:
- RPEP-15038
Evidence Hierarchy
Frequently Asked Questions
Why do psychiatric patients need special weight loss drug studies?
Psychiatric medications often cause significant weight gain, and some weight loss drugs can interact with psychiatric medications or worsen mental health symptoms. Evidence specific to this population ensures safe, effective treatment.
Which weight loss drug works best for psychiatric patients?
This study compared four options and found differences in effectiveness and side effects. The best choice depends on individual factors including which psychiatric medications a patient takes and which side effects they can tolerate.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-15038APA
Choi, Won-Seok; Song, Min-Kyu; Seo, Mansuk; Woo, Young Sup; Bahk, Won-Myong. (2026). Comparative efficacy and safety of liraglutide versus metformin, naltrexone/bupropion, and phentermine-topiramate in psychiatric patients.. Therapeutic advances in psychopharmacology, 16, 20451253261419609. https://doi.org/10.1177/20451253261419609
MLA
Choi, Won-Seok, et al. "Comparative efficacy and safety of liraglutide versus metformin, naltrexone/bupropion, and phentermine-topiramate in psychiatric patients.." Therapeutic advances in psychopharmacology, 2026. https://doi.org/10.1177/20451253261419609
RethinkPeptides
RethinkPeptides Research Database. "Comparative efficacy and safety of liraglutide versus metfor..." RPEP-15038. Retrieved from https://rethinkpeptides.com/research/choi-2026-comparative-efficacy-and-safety
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.